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Modern anesthesia has evolved markedly since William Clark et 
al., introduced vinyl ether in the mid nineteenth-century. That 
history, coupled with current clinical trends, provide context 
for considering future possibilities in Anesthesiology. Three 
dynamic components of  the field: 1) pharmaceutical agents, 2) 
information/mechanical technologies, and 3) human systems 
design can further evolve to improve patient safety and care in 
more efficient and socially conscious ways. 
Pharmaceuticals
Volatile anesthetic agents have been the backbone of  clinical 
anesthesia for 150 years. The neurophysiologic properties 
produced by vinyl ether allowed for creation of  an anesthetic state, 
and thus performance of  more complex surgical procedures. This 
discovery provoked the development of  better volatile agents: 
non-flammable, less toxic, and more predictable. Today, most 
anesthetics are conducted with one of  these highly fluorinated 
ethers: Isoflurane, Sevoflurane, or Desflurane. While each agent 
has distinct clinical utility, they share the debit of  being offensive 
greenhouse gases. Desflurane, for instance, under normal daily 
operating conditions produces greenhouse gases equivalent 
to driving fifty cars a day. Isoflurane and Sevoflurane, though 
roughly an order of  magnitude better, are still potent offenders 
[1]. A potential savior for gas-delivered-anesthesia exists in the 
noble gas xenon. Xenon can produce anesthesia with potential to 
offer significant cardio and neuro-protection without greenhouse 
effects [2]. While expensive and lacking clinical infrastructure, the 
promise of  xenon is inching its way into anesthesia practice.
Intravenous anesthetic agents/adjuncts have been used in 
various combinations since invention of  the hypodermic needle 
in the 1850s. While morphine continues to maintain broad clinical 
utility since being isolated from the poppy in the early nineteenth 
century, opioid derivatives have entered almost every facet of  
modern medicine. Notably, Remifentanil, with its very short 
context-sensitive-half-life (~5 minutes) and relative high potency 
(~100-200 times greater than morphine), has become a useful 
pharmacologic tool for the induction and maintenance of  total-
intravenous-anesthesia (TIVA): allowing both rapid titration of  
intense analgesia and rapid “awakening”. Moreover; of  particular 
interest to Pain specialists in the setting of  a national opioid 
epidemic, PZM21 is an experimental opioid that has the potential 
to offer analgesia with minimal untoward side effects. This could 
represent a paradigm shift in the treatment of  acute and chronic 
pain.
 
Barbituric acid is a hypnotic agent synthesized in 1864 that 
gained relevance in the early 1900's following discovery that it 
could produce "sleep" in dogs. Its clinical utility as an anti-
seizure medication followed, and also use in anesthesia. Sodium 
thiopental then came on-board. This shorter-acting agent allowed 
for rapid induction of  a general anesthetic state, transforming the 
ability of  the provider to secure the airway and control ventilation. 
However; since the late 1980s, Propofol has been the ubiquitous 
option as it can more rapidly induce/maintain general anesthesia 
and also provide for the full spectrum of  sedation.
Neuromuscular blocking agents, commonly called muscle relaxants 
or paralytic agents are also important to the specialty. Curare, 
a plant extract, achieved currency following isolation and 
synthesis in the early 1940s. This new category of  medications 
allowed for production of  a reliable paralytic state, and thus the 
ability to perform more complex surgical procedures. While the 
pharmaceutical industry has created a variety of  case-specific 
options, dynamic patient physiology or unexpected surgical timing 
can require that some patients be maintained under an anesthetic 
until they can be safely reversed from paralysis [3]. Sugammadex, a 
drug from a novel class of  reversal agents is beginning to change 
this equation. When properly administered after Rocuronium 
induced paralysis, Sugammadex rapidly forms a chemical-complex 
rendering Rocuronium inactive, and thus the immediate reversal 
of  the deep paralytic state [4]. Of  note, the overall necessity 
for paralytic use is decreasing as modern anesthetic agents have 
ancillary capacity to produce relaxation.
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Information/Mechanical Technologies
Data collection and record keeping can be traced back to the 
era of  vinyl ether anesthesia. Poor outcomes, including death, 
were common. Clinicians quickly realized the value of  biometric 
data, especially blood pressure and heart rate. In 1930, Elmer 
McKesson invented the automated intraoperative blood pressure 
machine called the Nargraf. This machine better allowed clinicians 
to respond to deviations in intraoperative patient physiology. 
Value was too placed on organizing such data into a standardized 
anesthesia account, a process that informs modern-day patient 
safety initiatives and other computer driven data analyses.
With these advancements however, clinicians are continuously 
challenged to determine data relevancy mid a deluge of  
information. As such, some medical centers have opted for 
real-time computerized clinical interactive feedback tools to 
help providers make better evidence based decisions. Systems 
can be programmed to alert providers to redose antibiotics per 
pharmacokinetic models, start insulin infusions when triggered 
by elevated glucose measurements, or issue warnings when other 
selected biometric boundaries are reached [5]. Modern electronic 
medical records integrate billing and coding for physicians and 
administrators: a template for efficiencies throughout healthcare. 
Medical devices likewise figure into evolving anesthetic practice. 
For example, with the advent of  volatilized ether for surgical use, 
initiatives followed to better administer anesthetic gases. None 
of  the early generation blow-by-gas glass-vaporizers were able to 
consistently deliver variable concentrations of  volatile anesthetics; 
that is, until Lucien Morris and Ralph Waters began work on the 
copper kettle in 1948. Within a few years, they revolutionized the 
delivery of  volatile anesthesia. Their chamber controlled the 
temperature of  the anesthetic while simultaneously percolating 
the carrier gas through the anesthetic liquid, and thus delivering 
known quantities of  vaporized anesthetic gas. For the first time, 
the provider could accurately adjust the depth of  anesthesia: 
another safety and quality milestone. The Draeger and Ohmeda 
Corporations now have vaporizers designed for specific anesthetic 
gases - products “smarter” than their predecessors–with no longer 
a need to perform lengthy calculations before each anesthetic. 
Other advancements have improved anesthetic care. A variety of  
case specific endotracheal tubes, supraglottic airways (laryngeal 
mask airways, oral airways, and nasal airways), and devices used to 
place these airways (curved/straight hand-held blades, fiber-optic 
bronchoscopes, and video laryngoscopes) exist today. Current 
ventilators reflect refinements in biomechanical engineering, and 
improved bedside ultrasound technologies continue advancement 
in the cardiovascular and regional anesthetic subspecialties. 
Other modern biometric devices allow real-time hemodynamic 
monitoring, exhaled gas analysis, and even practical use of  EEG 
profiles to determine depth of  anesthesia. 
In the future, much could be gained through technological 
advancement related to total-intravenous-anesthesia. Novel 
pump technology coupled with integrated novel medication 
storage is key; a device to deliver anesthetic medications with the 
touch of  a button – continuous infusions and rapid boluses on-
command. Properly configured, this could radically transform 
the field: the standard armamentarium of  medications turned 
on-demand, a new gold standard for TIVA to be followed by 
development of  pharmaceutical agents tailored to such capacity. 
In fact, Remimazolam (a super-short acting benzodiazepine) and 
ABP-700 (a super-short acting hypnotic) are currently under 
investigational status.
Human Systems Design/Patient Safety
Clinicians, colleagues, administrators, and educators do their 
best to facilitate interpersonal systems that build upon their 
predecessors’ pursuits. Diverse practice models, society-level 
initiatives, national and international work force allocations, payee 
reimbursement models, and education initiatives exist in today’s 
quilt of  anesthetic care. Political decision-making enters, with a 
complexity of  concerns that mandate separate discussion.
But most importantly, innovation in all realms of  anesthesia 
continues to improve patient safety. In fact, the safety improvement 
profiles in anesthesia are comparable to those found in the airline 
industry: often considered to be an industrial gold standard. Much 
of  this safety data can be traced to the Closed Claims Project, an 
ongoing initiative that compiles legal data as a metric for overall 
quality of  care [6].
And, we can always do better…
Disclosure
The author selected historical and contemporary illustrations 
without necessarily privileging these over others that readers may 
propose.
Acknowledgements
The author would like to thank The Wood Library Museum 
for their online resources, and also thank Dr. Andrew Bowdle 
and Professor Richard Baldasty for their assistance with this 
discussion.
References      
[1]. Ryan SM, Nielsen CJ (2010) Global warming potential of inhaled anesthet-
ics: application to clinical use. Anesth Analg. 111(1): 92-98. 
[2]. Maze M, Pirracchio R (2016) Will Xenon Be a Valuable Addition in Periop-
erative and Critical Care Settings? Anesth Analg. 122(3): 593-6. 
[3]. Thilen SR, Bhananker SM (2016) Qualitative Neuromuscular Monitoring: 
How to Optimize the Use of a Peripheral Nerve Stimulator to Reduce the 
Risk of Residual Neuromuscular Blockade. Curr Anesthesiol Rep. 6: 164-
169. 
[4]. Keating GM (2016) Sugammadex: A Review of Neuromuscular Blockade 
Reversal. Drugs. 76(10): 1041-52. 
[5]. Nair BG, Newman SF, Peterson GN, Wu WY, Schwid HA (2010) Feed-
back mechanisms including real-time electronic alerts to achieve near 100% 
timely prophylactic antibiotic administration in surgical cases. Anesth Analg. 
111(5): 1293-300. 
[6]. Cheney FW (1999) The American Society of Anesthesiologists Closed 
Claims Project: what have we learned, how has it affected practice, and how 
will it affect practice in the future? Anesthesiology. 91(2): 552-6. 
